Navigation Links
Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease
Date:4/10/2008

NEW YORK, April 10 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), announced today that it has obtained a Notice of Allowance and completed the grant requirements to obtain a European patent relating to the Company's ANTISENILIN(R) antibodies and products being developed by the Company for the treatment of Alzheimer's disease. Grant of the European patent is expected in several weeks. Other patents related to the ANTISENILIN(R) antibodies have been granted in Japan, China and elsewhere. Patent applications are pending in the United States. Intellect Neurosciences is the exclusive assignee of the ANTISENILIN(R) patents, which are based on the invention of Dr. Daniel Chain, the Company's Chairman and CEO.

Dr. Chain commented: "The use of ANTISENILIN(R) monoclonal antibodies that specifically target the toxic forms of beta amyloid is at the forefront of the battle against Alzheimer's disease. In addition to the Company's products in development, our invention has been applied to promising drug candidates in clinical development by major pharmaceutical companies."

"Intellect's ANTISENILIN(R) antibody technology incorporates an important safety feature ("free-end specificity"), meaning that antibodies developed using the technology are designed to specifically block the neurotoxicity of beta amyloid, which accumulates in the brains of Alzheimer's patients. The blocking of the neurotoxicity is achieved by promoting clearance of beta amyloid away from sites of damage while minimizing the potential for adverse effects," explained Professor Donald Price, Professor of Pathology, Neurology and Neuroscience and Founding Director of the Alzheimer's Disease Research Center at The Johns Hopkins School of Medicine and a member of Intellect's Scientific Advisory Board. Professor Price added: "Dr. Chain's idea of using antibodies in this way to reduce amyloid toxicity in the brain has gained considerable momentum over the past
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
5. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
6. Amarin Secures Global Intellectual Property Rights for Lipid Programs
7. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
8. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
9. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
10. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
11. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...v.24/PRNewswire-FirstCall/--NeurogesX,Inc.(Nasdaq:...ngandcommercializingnovelpainmanagementtherapies,a...xecutiveOfficer,isscheduledtopresentatthe21stAnnua...1-2,2009atTheNewYorkPalaceHotelinNewYork,NewYork. ...Officer,willbeavailabletorespondtoquestionsduringt...
(Date:11/24/2009)..., TORONTO,Nov.24/PRNewswire-FirstCall/-HamiltonT...eadingproviderofadvancedlasersystemsandinstruments...dayreportedoperationalandfinancialresultsforthethi...ts,-Revenuewas$1.46millioncomparedwith$1.43millio...with66.1percentinQ3,2008,-Netlossreducedto$148,000...
(Date:11/24/2009)...Program Connects Customers with Partners Validated... Genotek Products , Ottaw...a leading provider of products for biological samp...y announced its new global partner program. The pr...tek,s partner community and is designed to help pa...
(Date:11/23/2009)...es ultra-fast communication, computation and more ...t trying to use quantum states as carriers of info... physicists have shown, mathematically, how to gen...ion, while keeping the information intact. Their w...Review Letters and highlighted with a Viewpoint i...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...ALTO, Calif., Oct. 22 Varian, Inc.,(Nasdaq: VARI...TM) PCX, a,new addition to the Plexa family. Bond ...ration of polymers for solid phase extraction (SPE...l performance. SPE is used by,analytical chemists ...from,their surrounding sample matrices for analysi...
...ENA, Calif., Oct. 22 Maven Biotechnologies, LLC,a...abel-free multiplexing,immunodiagnostic analysis s...er a presentation at the BIOCOM Investor Conferenc...., Maven,s President and COO, will,present on Thur...otechnologies Maven Biotechnologies, LLC has deve...
...ny Sells 100,000th Pulse Oximetry Unit, NEW YORK,...OM), a leading developer of biosensor and micropro... devices, today announced that,is has sold its 100...as,been achieved within three years of the company...The bulk of the 100,000 units sold include the pat...
Other Biology Technology:New SPE Cation Exchange Technology From Varian Simplifies Extraction of Basic Compounds 2Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference 2SPO Medical Announces Major Sales Milestone 2SPO Medical Announces Major Sales Milestone 3
(Date:11/24/2009)..., The Lupus Research Institute (LRI) today named ...ling $3.6 million, recognize innovative work acros...ected for their creativity, novelty, and potential...nt, treat, and cure the complex disease of systemi...tablished lupus researchers across the nation and ...
(Date:11/24/2009)..., The atomic-level action of a remarkable class o... researchers with the Lawrence Berkeley National L...protein crystallography beamline at the Advanced L...al roles in gene expression and replication, and a...as well as infectious agents, such as the human pa...
(Date:11/24/2009)..., What constitutes fish food is a matter of deba... that fish get almost 50 percent of their carbon f...nk between the terrestrial and aquatic ecosystems....ngton shows this is not likely to be true. Algae p...ic life, according to research published this week...
Breaking Biology News(10 mins):Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Measuring Pain from the Patients Point of View 57738 1Measuring Pain from the Patients Point of View 57738 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 1BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 3BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 4BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 5Simbionix USA Corporations Innovative Development Division Releases Two New Breakthrough Technologies 14167 1Simbionix USA Corporations Innovative Development Division Releases Two New Breakthrough Technologies 14167 2
...cience University researchers have identified some...in damage caused by multiple sclerosis (MS), compl...d conditions. The findings offer important clues a... and suggest ways that at least some forms of brai...hed in the August edition of the scientific journa...
...n alien if you encountered it on the street tomorr...rld but rather was created in a laboratory right h... Earth life? , Either way, Peter Ward has the begi... of Washington paleontologist puts forth an expand...stem, to account for a variety of life forms that ...
...nvade the body, immune mechanisms kick in to fight...leted oxygen levels, and a protein called HIF-1 al...nsible for destroying the foreign pathogens are ef...tudy appearing in the July 1 print issue of The Jo...nd collegues from UCSD show for the first time tha...
Other Biology News:OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 2OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 3OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 4New book expands biological classifications to account for 'alien' life 2New book expands biological classifications to account for 'alien' life 3
Rabbit Anti-hCG Polyclonal Antibody, Unconjugated from Abcam
Sheep Anti-Human Indolamine (Indoleamine) 2,3-dioxygenase Antibody, Unconjugated from CHEMICON
Glutathione Agarose Beads from BD Biosciences Pharmingen
Mouse NFkB Signaling Pathway, PCR Array for expression profiling from SuperArray Bioscience
Biology Products: